Open Access<p>Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies</p>
Author(s) -
Renchi Yang,
Yongqiang Zhao,
Xuefeng Wang,
Jing Sun,
Runhui Wu,
Chenghao Jin,
Jie Jin,
Depei Wu,
Pablo Rendo,
Feifei Sun,
Jeremy Rupon,
Francois Huard,
Joan KorthBradley,
Lihong Xu,
Binyu Luo,
Yingxue Cathy Liu
Publication year - 2020
Publication title -
journal of blood medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.676
H-Index - 18
ISSN - 1179-2736
DOI - 10.2147/jbm.s241605
Subject(s) - medicine , rash , authorization , adverse effect , surgery , computer security , computer science
Moroctocog alfa albumin-free cell culture (AF-CC) increases plasma levels of factor VIII (FVIII) activity and, in China, is indicated for the control and prevention of bleeding episodes in patients with hemophilia A. This study aimed to evaluate the efficacy, safety, and recovery data of moroctocog alfa (AF-CC) in patients with hemophilia participating in two open-label studies, both conducted in China.